Breber Pierre R purchased $400K of CLX (indirect holdings)

Breber Pierre R purchased 4,000 indirectly-held shares of CLOROX CO /DE/ (CLX) at $100.06 ($0.40M total) on 2026-11-04.

Original reporting
SEC EDGAR · Breber Pierre R
Published Nov 5, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLX
Bullish
high confidence
Mentioned
$CLX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLXBullishLow
01

Why it matters

The filing provides fresh insider activity data, which may influence short-term sentiment.

02

Market read

New insider purchase information could prompt slight buying interest in CLX.

03

What to watch

No 10b5-1 plan and the director's overall stake remains a small percentage of float.

Relevance 5/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses a director's open-market purchase of CLX shares.

Company-level read

Ticker impact

$CLXBullishHigh confidence
Context

Director Breber Pierre R bought 4,000 CLX shares for $400,250, raising his holding to 22,000 shares.

Expected impact

modest upside pressure as market prices in the director's buy

Evidence & confidence

The purchase is a primary Form 4 filing, new information, and director buying is generally viewed as a bullish signal.

Market effects

Minimal impact on consumer staples sector; insider activity may be noted by sector traders.

U.S. market only; no broader regional effect.

Low global relevance.

Counterpoint

The purchase size is modest; could be routine portfolio rebalancing, not a strong bullish indicator.

Key entities

  • Clorox Co.

    Issuer of the shares purchased.

  • Breber Pierre R

    Director of Clorox and purchaser of the shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLXMedAI 8/10

Why is Clorox stock climbing today?

Clorox (CLX) stock rose 1.2% in pre-market trading after reporting fiscal Q1 earnings of $1.55 per share, beating estimates by 45%, with revenue of $1.91B. Sales increased 33% YoY, driven by the GOJO acquisition and organic growth. Analysts upgraded price targets (Evercore ISI to $99, Wells Fargo to $90, JPMorgan to $86), but Goldman Sachs maintained a Sell rating with a $74 target. Management warned of higher input costs and adjusted EPS guidance downward.

$CLXHighAI 8/10

Clorox Co (CLX) (Q1 2027) Earnings Call Highlights: Record Cost Savings and GoJo

Clorox (CLX) reported Q1 2027 earnings, with CEO Linda Rendell and CFO Kevin Bellet discussing organic sales growth of 3.5% to 4.5%, including ERP benefits. They highlighted record cost savings, targeted pricing, and market share improvements in home care and Brita. GoJo synergies are progressing faster than expected, with revised EPS estimates. The company aims for long-term gross margin of 43% to 44% and operating margin of 18%.

$CLXMed

Clorox (CLX) Q1 2027 Earnings Call Transcript

Clorox (CLX) reported Q1 2027 earnings, updating its outlook to reflect $240M in input cost inflation, driven by commodities and transportation. The company expects organic sales growth of 3.5% to 4.5% for the year, with a flat to slightly positive performance in the back half. Clorox also announced Fabian Garcia as its next CEO, effective January. The company is implementing cost savings and targeted pricing to mitigate inflationary pressures.

$CLXMed

Clorox Q1 Earnings Call Highlights

Clorox (CLX) maintained its fiscal-year organic-sales-growth outlook of 3.5% to 4.5%, with Q2 expected to range from flat to down 2%. The company reported share gains in home care, Brita, and Hidden Valley Ranch, while Kingsford and cat litter faced challenges. Clorox is prioritizing pricing, innovation, and GOJO integration, with Fabian Garcia appointed as the next CEO. The company expects positive adjusted EPS impact from synergies in fiscal 2027.